‘Include Duchenne’ project Decipha gets to finals of the National Lottery Awards 2011 - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

‘Include Duchenne’ project Decipha gets to finals of the National Lottery Awards 2011 - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "Voting for the semi-finals starts at 9am on Tuesday, 31st May and ends at midday on Monday, 20th June. We need your vote – you can either call the 0844 836 9683 or vote online at"

Parent Project Muscular Dystrophy: Home

Parent Project Muscular Dystrophy: Home: "The House deadline for Fiscal Year (FY) 2012 Labor-Health & Human Services (L-HHS) appropriations requests is Friday, May 20! As such, we need all Advocates to encourage their Representatives to support our FY 2012 funding priorities. Please take a few moments to contact your House member’s office and ask that he/she sign-on to our FY 2012 Duchenne muscular dystrophy appropriations letter and submit our FY 2012 report language."

Now Recruiting: MRI and Biomarkers for Duchenne Muscular Dystrophy Study (ImagingDMD)

Now Recruiting: MRI and Biomarkers for Duchenne Muscular Dystrophy Study (ImagingDMD): "This study focuses on developing Magnetic Resonance Imaging (MRI) as a tool to monitor disease progression in Duchenne and to serve as an outcome measure for clinical trials. The aim of the study is to determine whether noninvasive MRI outcome measures can replace muscle biopsies in evaluating the effectiveness of new treatments in future clinical trials. A second goal of this study is to characterize the progressive involvement of the lower extremity muscles to help guide the design of future clinical trials. This study is funded by the NIH – NIAMS/NINDS. "

Santhera Presents Data from 2-Year Open-Label Intervention Study with Catena® in Duchenne Muscular Dystrophy at the MYOLOGY 2011 Conference | Reuters

Santhera Presents Data from 2-Year Open-Label Intervention Study with Catena® in Duchenne Muscular Dystrophy at the MYOLOGY 2011 Conference | Reuters: "Santhera Pharmaceuticals (SIX: SANN) announced today that it will present first analyses of the 2-year open-label study (DELPHI-E) evaluating Catena® for the treatment of Duchenne Muscular Dystrophy. The findings indicate that Catena® can slow the decline in respiratory function associated with patients as they age. Data will be presented on May 9, 2011 in Lille, France at the 4th International Congress of Myology [1].
"

Daily treatment with SMT C1100 dramatically reduces muscular dystrophy symptoms in mdx mouse - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

Daily treatment with SMT C1100 dramatically reduces muscular dystrophy symptoms in mdx mouse - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "Summit plc based in Abingdon, UK, together with the Davies group (University of Oxford) and collaborators have reported exciting results from its latest studies of its utrophin upregulator drug SMT C1100. It has developed a small molecule based drug that can be taken orally once a day which could treat all patients with muscular dystrophy regardless of their specific gene defect. The studies took place using the mdx mouse, a recognised model for Duchenne Muscular Dystrophy study and in human tissues in the lab. The results showed increased utrophin in muscles and that this helped increase the amount of exercise achievable and therefore overall strength. These significant results demonstrate the potential importance of SMT C1100 and should pave the way for the next human trials of the drug."

Sildenafil/Taladafil Study at Cedars-Sinai Medical Center IRB-Approved

Sildenafil/Taladafil Study at Cedars-Sinai Medical Center IRB-Approved: "The sildenafil/taladafil study at Cedars-Sinai Medical Center is now IRB-approved and will begin recruiting patients in June."